SPATA17

SPATA17 is a testis-enriched protein that functions in spermatogenesis, with roles in germ cell apoptosis regulation and in the structural organization of the spermatozoal flagellum (PMID:16395525, PMID:39686771). In the adult testis it localizes to the cytoplasm of round and elongating spermatids, and its overexpression in spermatogonial GC-1 cells accelerates apoptosis in a dose-dependent manner (PMID:16395525); this pro-apoptotic effect is recapitulated in vivo, where spermatocyte-specific overexpression in transgenic mice increases apoptotic germ cells without gross testicular defects (PMID:23079716). In mature sperm, SPATA17 is a component of the C1a projection of the flagellar axoneme, and its proper expression along the flagellum depends on SPAG17-mediated axonemal integrity, since loss-of-function SPAG17 mutations disrupt SPATA17 distribution (PMID:39686771). The protein carries calmodulin-binding IQ motifs, indicating potential calcium/calmodulin-dependent regulation (PMID:21108043). Beyond these observations, the molecular activity and direct binding partners of SPATA17 have not been characterized in the available corpus.

1. 2006 Medium

   Establishing where SPATA17 acts and what cellular consequence it produces, the first study placed the protein in spermatid cytoplasm and linked its overexpression to germ cell apoptosis.

   Evidence Immunohistochemistry localization in mouse testis plus flow cytometry and Hoechst staining apoptosis assays following overexpression in GC-1 cells

   PMID:16395525

   Open questions at the time

   • Apoptotic pathway and effectors engaged by SPATA17 not identified
   • No loss-of-function evidence to establish endogenous role
   • Mechanism connecting localization to apoptosis unknown
2. 2009 Low

   To test whether SPATA17 contributes to meiosis in humans, a genetic association implicated a SPATA17 coding variant in meiotic arrest azoospermia.

   Evidence Sequencing of SPATA17 coding regions and SNP allele-frequency comparison across azoospermia patients and controls

   PMID:19483714

   Open questions at the time

   • Genetic association only, no functional test of the variant
   • Small cohort
   • Causal link to meiotic arrest unestablished
3. 2010 Low

   Probing how SPATA17 might be regulated, domain analysis identified calmodulin-binding IQ motifs and confirmed testis-predominant expression and the apoptotic phenotype.

   Evidence Bioinformatic IQ motif identification, multi-tissue RT-PCR/Northern blot, and flow cytometry/DNA ladder apoptosis assays in GC-1 cells (zebrafish ortholog)

   PMID:21108043

   Open questions at the time

   • IQ motif function not experimentally dissected
   • Calmodulin binding not demonstrated biochemically
   • No mechanistic link between IQ motifs and apoptosis
4. 2012 Medium

   Moving from cell lines to a whole-animal context, transgenic overexpression confirmed that elevated SPATA17 drives germ cell apoptosis in vivo.

   Evidence PGK2 promoter-driven SPATA17 transgenic mice with histology and apoptosis quantification in testis

   PMID:23079716

   Open questions at the time

   • Overexpression model does not reveal endogenous loss-of-function role
   • No fertility or structural defect observed, leaving physiological function unclear
   • Downstream apoptotic mediators not identified
5. 2024 Medium

   Defining a structural role in the mature gamete, SPATA17 was localized to the axonemal C1a projection and shown to depend on SPAG17 for proper flagellar distribution.

   Evidence Immunofluorescence and Western blot of human spermatozoa with homozygous SPAG17 mutations and TEM of axoneme cross-sections

   PMID:39686771

   Open questions at the time

   • Direct SPATA17-SPAG17 physical interaction not demonstrated
   • Functional contribution of SPATA17 to flagellar motility untested
   • Relationship between axonemal role and earlier apoptotic role unresolved

• The molecular activity of SPATA17 and the mechanism connecting its pro-apoptotic role in spermatids to its structural role in the flagellar axoneme remain undefined.
• No biochemical activity or direct binding partner established
• Calmodulin regulation predicted but unproven
• Endogenous loss-of-function phenotype not characterized